In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Correlogic Systems Inc.

Latest From Correlogic Systems Inc.

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover Covidien's acquisition of ev3, J&J's moves in the endovascular market, DePuy's launch of new products in hip revision, and FDA regulation of consumer genomics.
Medical Device

Controversies in Proteomics

A Lancet paper published two years ago detailing a promising but highly novel approach to detecting ovarian cancer, one of the deadliest cancers, continues to be the subject of great controversy in cancer circles. The test uses proteomic pattern profiling to detect the cancer, with a more than 95% accuracy in early studies, but no one knows what the patterns are made of. The NCI and two large reference labs are pushing ahead to get the test into the clinic, on the premise that as long as it is so good at detecting cancer, a lack of understanding of the underlying biochemistry isn't an insurmountable hurdle to acceptance.
Medical Device Clinical Trials

NCI's New Emphasis on Benchtop to Bedside

The private sector, short of funding, is finding NIH a useful source of support. As large-scale biomedical research becomes prevalent and as industry's early-stage R&D productivity falters, both parties have an interest in collaborating more than in the past. But in general, NIH isn't set up to manage the transformation of so many promising discoveries into clinically useful products. It's determined to change that situation with the introduction in October of this year of a "roadmap" for collaborations of many kinds. Even before this event, however, NCI, the largest institute within NIH, had undertaken several public-private programs to expedite development of new products. The institute's experiences illustrate some of advantages and pitfalls of public-private initiatives.
BioPharmaceutical Business Strategies

Exact Sciences' Moment

Exact Sciences and its distribution partner, LabCorp are on the verge of launching a new molecular test for colon cancer screening. They've taken deal-making in diagnostics to a new level, but now they have to deliver on their promises.
Medical Device Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • In Vitro Diagnostics
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Correlogic Systems Inc.
  • Senior Management
  • Peter J Levine, Pres. & CEO
    Tim Coleman, PhD, VP, R&D
  • Contact Info
  • Correlogic Systems Inc.
    Phone: (301) 214-4030
    6701 Democracy Blvd.
    Ste. 300
    Bethesda, MD 20817